JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB310749

Alexa Fluor® 594 Anti-CD79b antibody [EPR6861]

Be the first to review this product! Submit a review

|

(0 Publication)

Rabbit Recombinant Monoclonal CD79b antibody - conjugated to Alexa Fluor® 594.

View Alternative Names

CD79b, B29, IGB, CD79B, B-cell antigen receptor complex-associated protein beta chain, B-cell-specific glycoprotein B29, Ig-beta, Immunoglobulin-associated B29 protein

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR6861

Isotype

IgG

Conjugation

Alexa Fluor® 594

Excitation/Emission

Ex: 590nm, Em: 617nm

Carrier free

No

Applications

Target Binding Affinity, Antibody Labelling

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

style
left-column
style
left-column

Product details

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

style
left-column

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle|Store in the dark
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CD79b also known as Ig-beta is a protein that plays a mechanical role as part of the B-cell antigen receptor complex. This protein with a mass of approximately 40 kDa is mainly expressed on the surface of B lymphocytes. It is an important component of the heterodimeric complex composed of CD79a (Ig-alpha) and CD79b which associates with membrane-bound immunoglobulins to form the B-cell receptor (BCR). CD79b is essential for transducing activation signals following antigen binding to the BCR.
Biological function summary

The primary role of CD79b within the immune system is to support signal transduction. Upon binding of an antigen to BCR on B cells CD79b as part of the BCR complex initiates signaling cascades which lead to B-cell activation proliferation and differentiation. These processes are critical for humoral immunity ensuring adequate antibody production. CD79b is often found in association with CD19 another important B-cell surface protein and together they aid in amplifying the signals required for B-cell response.

Pathways

CD79b is deeply involved in the B-cell receptor signaling pathway and the broader adaptive immune response. Once the BCR is engaged by an antigen CD79b helps activate intracellular signaling pathways that involve kinases such as SYK and BLNK which help propagate and amplify the immune response. These pathways also interact with other receptor components like CD22 and CD19 creating a network of interactions ensuring effective pathogen recognition and response.

CD79b carries significant relevance in the context of B-cell malignancies such as chronic lymphocytic leukemia (CLL) and some types of lymphoma. Dysregulation or mutations in CD79b can affect BCR signaling leading to unchecked B-cell proliferation characteristic of these diseases. Additionally CD79b's interaction with proteins such as SYK in the signaling pathways makes it a potential therapeutic target in treating B-cell related cancers. Researchers are actively investigating anti-CD79b therapies to disrupt abnormal signaling in B-cell malignancies.
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

Required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation.
See full target information CD79B
style
left-column
style
left-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions
style
left-column
style
right-column

Associated Products

Select an associated product type
Alternative Version
Primary Antibodies

AB240083

Anti-CD79b antibody [EPR6861] - BSA and Azide free

primary-antibodies

cd79b-antibody-epr6861-bsa-and-azide-free-ab240083

0

(0 reviews)

style
bg-slate-100

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com